-
Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval for its Vericor peripheral support catheter from the Thailand Food and Drug Administration. This development marks a significant step for the company as it expands the reach of its medical devices in the Southeast Asian…
-
CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
•
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a Phase II trial for its pipeline candidate CAN008 (asunercept) in combination with temozolomide for the treatment of glioblastoma multiforme (GBM). The multi-center, randomized, placebo-controlled study, which is potentially registrational, has recruited a total of 117…
-
Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
•
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing for its in-house developed Category 1 biological product, Xeligekimab, for the treatment of moderate to severe plaque psoriasis has been accepted for review. This development marks a significant step forward for the company and the…
-
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022. As of December 31, 2022, the company reported revenues of RMB 9.382 billion (USD 1.362 billion), a decrease of 5.6% year-on-year (YOY). Despite this, the sales revenue of innovative drugs reached RMB 5.006 billion (USD…
-
National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety
•
The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual Report (2022)”, providing insights into the adverse drug reaction (ADR) landscape in China. The National Adverse Drug Reaction Monitoring Network received 2,023,000 ADR/Event Report Forms and 642,000 new and serious ADR/Event reports during the year.…
-
China’s New Internet Advertising Regulations Impact Pharmaceutical Sector
•
The State Administration for Market Regulation has released the latest version of the “Measures for the Administration of Internet Advertising,” which came into effect on May 1, 2023. The new rules have significant implications for the pharmaceutical industry, including the following key points: Prohibition on Internet Advertising of Prescription DrugsThe…
-
Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for 2022, highlighting revenues of RMB 43.952 billion (USD 6.381 billion), marking a 12.66% increase year-on-year (YOY). The company’s net profits also saw a significant rise, reaching RMB 3.873 billion (USD 562.4 million), up 18.17%…
-
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency Use Authorization (EUA) for its in-house developed COVID-19 mRNA vaccine, SYS6006, in China. This approval marks a significant milestone as it is the first for a domestically developed mRNA product in the country. Design and…
